Curis, Inc.

CRIS Healthcare Biotechnology

Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024. In the quarter to June 2026, revenue fell 66.0%, EPS grew 70.4% and free cash flow fell 20.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.41 0.10 −19.61%
Market cap
$1.1M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
4/9
Altman Z
−87.83
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— — 4 4

+8 more TTM periods

ROE
455.35% (693.95%) 2,829.10% 312.10%
ROA
(87.76%) (61.34%) (24.77%) (104.28%)
ROIC
0.00% 0.00% (890.43%) 0.00%
Return on Tangible Assets
306.34% (1,251.63%) 106.80% 618.86%
Average Days of Receivables
— — 0.00 101.60
Free Cash Flow per Share
(14.32) (29.90) (41.33) (38.38)
Free Cash Flow
(30.59) (28.95) (27.20) (30.09)
Other line items

Show all line items

Columns are period end dates